An atlas of genetic influences on human blood metabolites

Shin et al., Nature Genetics, 2014 [ Article | SI Text ]

Locus 56: SLC22A1|SLC22A2 (6q25.3)

Meta-analysis summary statistics for associations meeting genome-wide significance
Lead SNPBiochemicalsEA/OANtotalEAFEffect (SE)PmetaDetails
rs316020 X-12798 / phenylalanine A/G 7100 0.09 -0.183 (0.005) 2.77·10-286 show
rs316019 X-12798 A/C 7119 0.09 -0.181 (0.005) 1.56·10-259 show

EA = effect allele; OA = other allele; EAF = frequency of effect allele;

Summary of biological annotations
SNPrs316020
Chromosomal locationChr6: 160,589,071 (6q25.3)
Gene (distance)SLC22A2 (0)
Predicted causal geneSLC22A1
Gene/protein classificationtransporter/transporter
Metabolite (Pathway)X-12798 (Unknown)
phenylalanine (Phenylalanine & tyrosine metabolism; Amino acid)
Biochemical locus-metabolite relationshipSLC22A1 and SLC22A2 encode the Oct1 and Oct2 organic cation transporters. These transporters are not known to specifically transport phenylalanine, but Oct1 has been shown to transport dopamine, a neurotransmitter which can be synthesized from phenylalanine [9260930]. Ratio interpretation: n/a.
eQTL associations-

 

Medical information
Complex trait associations-
Known metabolite associationsX-12798 [23093944]
Inborn error of metabolism-

Pharmacological information
ChEMBL IDCHEMBL5685, CHEMBL1743122
Drug information Substrates of SLC22A1: Tetraethylammonium, N-methylpyridinium, metformin*, oxaliplatin; Inhibitors of SLC22A1: Quinine, quinidine, disopyramide; Substrates of SLC22A2: N-Methylpyridinium, tetraethylammonium, metformin*, pindolol, procainamide, ranitidine amantadine, amiloride, oxaliplatin, varenicline; Inhibitors of SLC22A2: Cimetidine*, pilsicainide, cetirizine*, testosterone, quinidine; (PMID: 20190787)

Locus information for top associated metabolite

HapMap2 imputation

Imputation HapMap

1KGP imputation

Imputation 1KGP

 

Network view
Association map